chufangao/CTO huggingface dataset:
Clinical trial NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Official title: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor has decided to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants. This decision was made without any safety concerns.
Enrollment: 159.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-11
Primary completion date: 2023-12-11
Completion date: 2023-12-11
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Clinical trial NCT03870529: High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
Official title: A Pilot Study of Neoadjuvant High Dose Vitamin A for Resectable Non-Small Cell Lung Cancer
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Slow accruals
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-19
Primary completion date: 2022-12-09
Completion date: 2022-12-09
Plan to share individual participant data: NO
Clinical trial NCT04588727: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Official title: A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3366 in Healthy Men and Women of Non-Childbearing Potential Following: Part A: Single Ascending Dose Administration (Including Populations of Japanese and Chinese Subjects) Part B: Single Dose Administration of AZD3366 at One Dose Level or Placebo With Concomitant Repeated Dosing of Ticagrelor and Acetylsalicylic Acid
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 10.0
Start date: 2020-10-15
Primary completion date: 2022-01-19
Completion date: 2022-01-19
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT02464228: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Official title: An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
Acronym: PTCL
Sponsor: Kura Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-25
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Baseline population: The All Subjects as Treated (ASaT) Population consists of all enrolled subjects who received at least 1 dose of tipifarnib.
Clinical trial NCT06369077: How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?
Official title: Cross-over Comparison of Latanoprost QOD With Dor-tim QAM to Tim-brim-dor-bim(Atoprost) qd or Lat QD With Dor-tim BID
Sponsor: CT Glaucoma Associates (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The 95% confidence interval for non-inferiority was met before planned enrollment was reached.
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-04-22
Primary completion date: 2024-07-30
Completion date: 2024-07-30
Plan to share individual participant data: NO
Clinical trial NCT04516291: A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Official title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants With Dyslipidemia
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 286.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-09-28
Primary completion date: 2021-09-29
Completion date: 2021-12-06
Baseline population: Baseline analysis population included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03548987: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Official title: Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During run-in Period
Acronym: STEP 4
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 902.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-04
Primary completion date: 2020-02-22
Completion date: 2020-03-20
Baseline population: Full analysis set (FAS) included all randomised participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04939662: Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
Official title: Phase II, Single-arm Study of Olaparib and Bevacizumab Combination Therapy in Relapsed Small Cell Lung Cancer Subjects With DNA Damage Response and the Repair Pathway Alteration, ATM Deficiency, SLFN11 Positive, or POU2F3 Positive
Acronym: SUKSES-B2
Sponsor: Samsung Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-11
Primary completion date: 2023-10-27
Completion date: 2023-10-27
Clinical trial NCT04989972: Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults
Official title: Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults
Sponsor: Wake Network, Inc. (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: GCP VIOLATIONS FROM THE SPONSORS
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-15
Primary completion date: 2023-06-20
Completion date: 2023-08-31
Plan to share individual participant data: NO
IPD sharing description: The data will be made available through publications and conference presentations
Clinical trial NCT03804515: A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Official title: A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Sponsor: Spectrum Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: COVID
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-25
Primary completion date: 2020-02-20
Completion date: 2020-06-17
Clinical trial NCT03874325: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Official title: A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab (MEDI4736) in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lost funding
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-26
Primary completion date: 2020-11-15
Completion date: 2021-01-06
Baseline population: Study terminated early and did not go beyond Safety run in
Clinical trial NCT04344041: COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Official title: COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Sponsor: University Hospital, Angers (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 260.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-15
Primary completion date: 2021-01-14
Completion date: 2021-01-14
Clinical trial NCT04361214: Leflunomide in Mild COVID-19 Patients
Official title: Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated by PI
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-05
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT04338828: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED
Official title: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department
Acronym: NO COV-ED
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Absence of patients meeting criteria following initial COVID surge. DMSB recommended analysis of results to date and early closure.
Enrollment: 47.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-18
Primary completion date: 2021-01-14
Completion date: 2021-03-01
Plan to share individual participant data: NO
Clinical trial NCT04446182: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
Official title: A Phase II Study of Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic Graft Versus Host Disease (GVHD)
Acronym: FLIGHT
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI left institution
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-29
Primary completion date: 2022-03-29
Completion date: 2023-01-30
Plan to share individual participant data: NO
Clinical trial NCT03840148: Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
Official title: A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
Acronym: CERTAIN-1
Sponsor: Venatorx Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 661.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-07
Primary completion date: 2021-12-14
Completion date: 2021-12-14
Baseline population: Intent-to-treat (ITT) population: all randomized patients
Clinical trial NCT02654223: Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Official title: Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Acronym: MG56
Sponsor: Inmunotek S.L. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 9.0
Start date: 2015-12-30
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT04909879: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
Official title: Treatment of Non-COVID-19 Acute Respiratory Distress Syndrome: A Phase 2 Study of the Efficacy and Safety of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Replaced by a different protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-30
Primary completion date: 2022-02-28
Completion date: 2022-04-30
Clinical trial NCT03339336: Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
Official title: A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision to close study early; not due to safety concerns
Enrollment: 265.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-31
Primary completion date: 2021-04-12
Completion date: 2021-04-12
Clinical trial NCT03922620: Liposomal Bupivacaine vs Peripheral Nerve Block
Official title: Liposomal Bupivacaine vs Peripheral Nerve Block
Sponsor: Geisinger Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Additional published information on the topic since starting the study
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-23
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Baseline population: Only 1 baseline participant included as only 1 total participant was enrolled in the study.
Clinical trial NCT02706015: Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
Official title: National, Phase III, Multicenter, Randomized, Double-Blind, Parallel, Non-Inferiority Trial to Evaluate the Efficacy and Safety of Cefaliv® Compared to the Neosaldina® in the Treatment of Migraine Attacks
Sponsor: Ache Laboratorios Farmaceuticos S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Strategic reasons of the company
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-31
Primary completion date: 2021-05-31
Completion date: 2021-07-31
Clinical trial NCT02811497: Study of Azacitidine and Durvalumab in Advanced Solid Tumors
Official title: An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)
Acronym: METADUR
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-30
Primary completion date: 2018-11-08
Completion date: 2020-08-04
Clinical trial NCT03905902: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Official title: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Acronym: VITALIA
Sponsor: Sotio Biotech Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-31
Primary completion date: 2021-08-31
Completion date: 2021-08-16
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05712278: A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Official title: A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-06-16
Primary completion date: 2024-02-23
Completion date: 2024-03-12
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02300194: Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures
Official title: Topical Morphine for Analgesia in Pediatric Procedures. Clinical Trial Randomized, Double-blind, Placebo.
Sponsor: Hospital General de Niños Pedro de Elizalde (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Withdrawn by investigators
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT03427125: A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Official title: A 26-Wk, Phase 3, Open Label (OL) Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period and an OL Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in CKD Patients on Dialysis
Sponsor: Ardelyx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1559.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-01-08
Primary completion date: 2019-11-15
Completion date: 2020-02-27
Baseline population: Placebo was only used in the randomized withdrawal period (RWP). In the RWP, patients from the tenapanor (TEN) group were randomized 1:1 to either remain on TEN or receive a matching placebo. The patients on Sevelamer were not included in this part of the protocol.
Clinical trial NCT04667104: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Official title: A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Acronym: PENGUIN
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-01
Primary completion date: 2022-05-16
Completion date: 2023-04-17
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Clinical trial NCT03606980: Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics
Official title: Iontophoresis With Dexamethasone in Combination With Physical Therapy for the Treatment of Pediatric Patients Diagnosed With Apophysitis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
Sponsor: Children's Health System, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-05
Primary completion date: 2021-12-22
Completion date: 2023-03-01
Limitations and caveats: Our study was limited by limited enrollment, primarily as a result of the COVID-19 pandemic. Slow enrollment following the pandemic led to early closure of the study.
Plan to share individual participant data: NO
Clinical trial NCT03998293: Direct Measurement of Proinsulin Clearance in Humans
Official title: Direct Measurement of Proinsulin Clearance in Humans
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Newly available data suggests that measuring proinsulin clearance would not enhance predictive value of serum proinsulin
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-30
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT01817751: Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Official title: Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-04-11
Primary completion date: 2020-08-27
Completion date: 2023-05-12
Plan to share individual participant data: NO
Clinical trial NCT04243850: REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
Official title: A Single-center, Prospective, Placebo-controlled, Double-blind, Randomized, Cross-over Mechanistic Intervention Study to Investigate the Effect of Empagliflozin on Kidney Function in People With Either Preserved or Impaired Kidney Function With or Without Type 2 Diabetes
Acronym: REGROUP
Sponsor: Amsterdam UMC, location VUmc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: COVID
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-01
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04188639: Emicizumab in Acquired Hemophilia A
Official title: Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial
Sponsor: GWT-TUD GmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-23
Primary completion date: 2023-01-04
Completion date: 2023-01-04
Plan to share individual participant data: NO